List view / Grid view

Living Cell Technologies Limited (LCT)

 

news

NTCELL Phase I/IIa study meets endpoints

15 June 2015 | By Victoria White

A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints...